Literature DB >> 30583965

The relevance of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentration for postoperative infections and postoperative organ dysfunctions in cardiac surgery patients: The eVIDenCe study.

Julia Ney1, Daren K Heyland2, Karin Amrein3, Gernot Marx4, Oliver Grottke5, Michael Choudrakis6, Teresa Autschbach7, Aileen Hill5, Patrick Meybohm8, Carina Benstoem4, Andreas Goetzenich7, Christina Fitzner4, Christian Stoppe9.   

Abstract

BACKGROUND & AIMS: Recent studies indicate that vitamin D deficiency is associated with increased morbidity and mortality in critically ill patients. Knowledge about the functional role and clinical relevance of vitamin D for patients undergoing cardiac surgery is sparse. Therefore, we investigated the clinical significance of vitamin D levels on outcome of cardiac surgery patients.
METHODS: 92 patients undergoing elective cardiac surgery with cardiopulmonary arrest were included in this prospective observational pilot study. 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were measured prior to surgery, immediately postoperatively as well as 6, 12 and 24 h after surgery. We assessed postoperative organ dysfunctions, infections and death until hospital discharge.
RESULTS: The serum concentration of 1,25(OH)2D significantly decreased intraoperatively by 29.3% (p < 0.001) and was significantly lower at any postoperative time point compared to baseline values, whereas 25OHD levels did not show significant changes during the observation period. Coronary artery bypass graft (CABG) patients had significant higher baseline 1,25(OH)2D values than patients with valve surgery (39.7 ± 13.9 ng/l vs. 30.1 ± 14.1 ng/l, p = 0.010) or CABG + valve surgery (39.7 ± 13.9 ng/l vs. 32.6 ± 11.8 ng/l, p = 0.044). Our data showed a significant odds ratio to develop postoperative organ dysfunction (OR 0.95; p = 0.009) and PCT levels ≥5 μg/l (OR 0.94; p = 0.046) for every ng/l increment in 1,25(OH)2D, when performing multivariable analysis and after adjusting for preoperative illness and demographics. In addition, multivariable-adjusted statistical analyses revealed that patients stayed significantly shorter on ICU (-0.21 h; p = 0.001) and in hospital (-2.6 days; p = 0.009) for every ng/l increment in 1,25(OH)2D.
CONCLUSION: Our data highlight important evidence about the clinical significance of 1,25(OH)2D levels in cardiac surgery patients. Higher levels were associated with significantly less postoperative organ dysfunctions, elevated PCT levels, death and prolonged hospital stay. 1,25(OH)2D levels decreased significantly intra- and postoperatively, while serum levels of 25OHD did not. TRIAL REGISTRATION: clinicaltrials.gov (NCT02488876), registered May 1, 2015.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  1,25-Dihydroxyvitamin D; Cardiac surgery patients; Clinical outcome; Organ dysfunctions; Postoperative infections; Vitamin D deficiency

Year:  2018        PMID: 30583965     DOI: 10.1016/j.clnu.2018.11.033

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  8 in total

1.  Vitamin D deficiency in critically ill COVID-19 ARDS patients.

Authors:  Quirin Notz; Johannes Herrmann; Tobias Schlesinger; Peter Kranke; Magdalena Sitter; Philipp Helmer; Jan Stumpner; Daniel Roeder; Karin Amrein; Christian Stoppe; Christopher Lotz; Patrick Meybohm
Journal:  Clin Nutr       Date:  2021-03-07       Impact factor: 7.643

2.  Vitamin D supplementation for the treatment of COVID-19: a living systematic review.

Authors:  Julia Kristin Stroehlein; Julia Wallqvist; Claire Iannizzi; Agata Mikolajewska; Maria-Inti Metzendorf; Carina Benstoem; Patrick Meybohm; Marie Becker; Nicole Skoetz; Miriam Stegemann; Vanessa Piechotta
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

3.  Vitamin D supplementation protects against reductions in plasma 25-hydroxyvitamin D induced by open-heart surgery: Assess-d trial.

Authors:  Tyler Barker; Heidi T May; John R Doty; Donald L Lappe; Kirk U Knowlton; John Carlquist; Kristin Konery; Shannon Inglet; Ben Chisum; Oxana Galenko; Jeffrey L Anderson; Joseph B Muhlestein
Journal:  Physiol Rep       Date:  2021-02

4.  Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study.

Authors:  Emma A Hurst; Richard J Mellanby; Ian Handel; David M Griffith; Adriano G Rossi; Timothy S Walsh; Manu Shankar-Hari; Jake Dunning; Natalie Z Homer; Scott G Denham; Kerri Devine; Paul A Holloway; Shona C Moore; Ryan S Thwaites; Romit J Samanta; Charlotte Summers; Hayley E Hardwick; Wilna Oosthuyzen; Lance Turtle; Malcolm G Semple; Peter J M Openshaw; J Kenneth Baillie; Clark D Russell
Journal:  BMJ Open       Date:  2021-10-22       Impact factor: 2.692

Review 5.  Administration of vitamin D and its metabolites in critically ill adult patients: an updated systematic review with meta-analysis of randomized controlled trials.

Authors:  Johannes Menger; Zheng-Yii Lee; Quirin Notz; Julia Wallqvist; M Shahnaz Hasan; Gunnar Elke; Martin Dworschak; Patrick Meybohm; Daren K Heyland; Christian Stoppe
Journal:  Crit Care       Date:  2022-09-06       Impact factor: 19.334

Review 6.  Effects of Oxidative Stress on Protein Translation: Implications for Cardiovascular Diseases.

Authors:  Arnab Ghosh; Natalia Shcherbik
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

7.  Vitamin D Status and Pregnancy Complications: Serum 1,25-di-hydroxyl-Vitamin D and its Ratio to 25-hydroxy-Vitamin D are Superior Biomarkers than 25-hydroxy-Vitamin D.

Authors:  Ibrahim A Albahlol; Abdulrahman H Almaeen; Abdulrahman A Alduraywish; Umar F Dar; Tarek H El-Metwally
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

Review 8.  Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices.

Authors:  Gennaro Martucci; Federico Pappalardo; Harikesh Subramanian; Giulia Ingoglia; Elena Conoscenti; Antonio Arcadipane
Journal:  Nutrients       Date:  2021-03-05       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.